Analysis Of Income And Expense [Abstract]

Biofrontera AG - Filing #6537419

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Interest income
1,000 EUR
13,000 EUR
Revenue
25,738 EUR
28,787 EUR
Material income and expense [abstract]
Research and development expense
7,128 EUR
7,009 EUR
Other finance income
44,172 EUR
14,729 EUR
Interest expense
163,000 EUR
3,692 EUR
Interest expense on debt instruments issued
0 EUR
28,000 EUR
Expenses by nature [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation expense
746,000 EUR
3,290 EUR
Disclosure of attribution of expenses by nature to their function [text block]
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
0 EUR
1,866 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
0 EUR
44,166 EUR
44,166 EUR
0 EUR
0 EUR
33,286 EUR
0 EUR
1,866 EUR
0 EUR
31,420 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
44,166 EUR
31,420 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.